Page 175 - DOS Kongressen 2012 - Abstracts

135.
The Prognostic Value of 18F-FDG PET/CT in the Initial Assessment
of High-grade Bone and Soft Tissue Sarcomas
Hanna Maria Fuglø, Simon Møller Jørgensen, Annika Loft, Dorrit Hovgaard,
Michael Mørk Petersen
Department of Orthopaedic Surgery Rigshospitalet, Copenhagen University
Hospital; Department of Clinical Physiology, Nuclear Medicine & PET,
Rigshospitalet, Copenhagen University Hospital; Department of Clinical
Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University
Hospital; Department of Orthopaedic Surgery, Rigshospitalet, Copenhagen
University Hospital; Department of Orthopaedic Surgery, Rigshospitalet,
Copenhagen University Hospital
Background:
Today the histological malignancy grade is the best predictor for
survival in most patients with soft tissue (STS) and bone sarcomas (BS).
Purpose / Aim of Study:
Evaluate if the degree of FDG uptake which
indicates the degree of tumour metabolism in the primary tumour is of
prognostic value in STS and BS.
Materials and Methods:
During the years 2001-2010, 68 patients (mean age
44 (11-86)
years, F/M=35/33) with a high-grade sarcoma (BS/STS=28/40) had
a preoperative PET/CT performed for staging purpose. From the original scan
data the maximal standardized uptake value (SUVmax) of the primary tumour
was calculated and the material divided into respectively two (10
¡
ÝSUVmax>10) and three groups (SUVmax: 0-7; 7.1-14 ; >14). Data for
patient survival was obtained from the Danish Centralised Civil Register on
June 8th 2011. Statistics: Kaplan-Meier survival analysis.
Findings / Results:
22
patients (32 %) died during follow-up (average
survival was 6.2 years). In the group with SUVmax ¡Ü10 5 patients died,
whereas in the group with SUVmax >10 17 patients died. The probability of 5-
year survival in the group with SUVmax ¡Ü10 was 81 % and in the other
group (>10) 33 %. The average survival within the groups were 8.1 years (95
%
CI: 6.9- 9.2 years) and 2.3 years (95 % CI: 1.7- 3.0 years) for SUVmax
¡
Ü10 and >10, respectively. In the group with SUVmax 0-7 (n=24) two
patients died, in the group 7.1-14 (n=20) 7 patients died and in the group with
SUVmax >14 (n=24) 13 patients died during follow-up. The probability of 5-
year survival was 89%, 57%, 27% and the average survival 8.7 years (95% CI:
7.8-9.8
years); 4.6 years (95 % CI: 3.2-6.0 years) and 2.2 years (95% 1.4-2.9
years) for SUVmax levels of 0-7, 7.1-14 and >14, respectively.
Conclusions:
The SUVmax of the primary tumour was a strong prognostic
factor for survival in patients with high-malignant STS and BS.